Cargando…

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review

BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLI...

Descripción completa

Detalles Bibliográficos
Autores principales: Wani, Mudassir M., Sheikh, Mohammad I., Bhat, Tahir, Bhat, Zubair, Bhat, Arshad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451319/
https://www.ncbi.nlm.nih.gov/pubmed/34552455
http://dx.doi.org/10.1097/CU9.0000000000000037
_version_ 1784569817530892288
author Wani, Mudassir M.
Sheikh, Mohammad I.
Bhat, Tahir
Bhat, Zubair
Bhat, Arshad
author_facet Wani, Mudassir M.
Sheikh, Mohammad I.
Bhat, Tahir
Bhat, Zubair
Bhat, Arshad
author_sort Wani, Mudassir M.
collection PubMed
description BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLINE, PUBMED, and EMBASE. All relevant published articles during last 5 years with full texts available were included in this review for critical analysis and evaluation. In total, there were 20 studies including 7 systemic reviews, 6 retrospective cohort, 3 prospective cohort, 2 randomized controlled trials, and 2 cross sectional studies. RESULTS: After critical evaluation the results were considered under parameters of efficacy, adverse effects, adherence and persistence, tolerability, cost-effectiveness. In 9 studies efficacy was evaluated, 5 studies dealt with adverse effects, same number evaluated adherence and persistence. Cost effectiveness was compared in 3 and same number of studies also compared tolerability. CONCLUSIONS: To conclude, we found mirabegron is as efficacious as any other antimuscarnics, has better tolerability (including elderly), has better adverse effect profile, is cost effective, has better persistence and adherence rates at 12 months.
format Online
Article
Text
id pubmed-8451319
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84513192021-09-21 Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review Wani, Mudassir M. Sheikh, Mohammad I. Bhat, Tahir Bhat, Zubair Bhat, Arshad Curr Urol Review BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLINE, PUBMED, and EMBASE. All relevant published articles during last 5 years with full texts available were included in this review for critical analysis and evaluation. In total, there were 20 studies including 7 systemic reviews, 6 retrospective cohort, 3 prospective cohort, 2 randomized controlled trials, and 2 cross sectional studies. RESULTS: After critical evaluation the results were considered under parameters of efficacy, adverse effects, adherence and persistence, tolerability, cost-effectiveness. In 9 studies efficacy was evaluated, 5 studies dealt with adverse effects, same number evaluated adherence and persistence. Cost effectiveness was compared in 3 and same number of studies also compared tolerability. CONCLUSIONS: To conclude, we found mirabegron is as efficacious as any other antimuscarnics, has better tolerability (including elderly), has better adverse effect profile, is cost effective, has better persistence and adherence rates at 12 months. Lippincott Williams & Wilkins 2021-09 2021-08-17 /pmc/articles/PMC8451319/ /pubmed/34552455 http://dx.doi.org/10.1097/CU9.0000000000000037 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Review
Wani, Mudassir M.
Sheikh, Mohammad I.
Bhat, Tahir
Bhat, Zubair
Bhat, Arshad
Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title_full Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title_fullStr Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title_full_unstemmed Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title_short Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
title_sort comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: a literary review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451319/
https://www.ncbi.nlm.nih.gov/pubmed/34552455
http://dx.doi.org/10.1097/CU9.0000000000000037
work_keys_str_mv AT wanimudassirm comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview
AT sheikhmohammadi comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview
AT bhattahir comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview
AT bhatzubair comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview
AT bhatarshad comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview